---

2023

Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones	October 20, 2023
Nicox Provides Second Quarter 2023 Financial and Business Highlights	July 19, 2023
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux (as of June 30, 2023)	July 11, 2023
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million	July 10, 2023
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress	July 3, 2023
Nicox: 2023 Ordinary Shareholder Meeting	June 2, 2023
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China	April 28, 2023
Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023	April 26, 2023
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023	April 26, 2023
Shareholders Letter – April 2023	April 24, 2023
Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1, 2023	April 24, 2023
Nicox Provides First Quarter 2023 Financial and Business Highlights	April 19, 2023
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China	April 14, 2023
Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congress	March 21, 2023
Nicox Reports 2022 Financial Results and Updates Key Future Milestones	March 20, 2023
Nicox to Present at Upcoming Scientific Conferences	March 3, 2023
Nicox: Ordinary Shareholder Meeting of February 28, 2023 – Approval of all Resolutions	March 1, 2023
Nicox’s Ordinary Shareholder Meeting to be held on February 28, 2023	February 13, 2023
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023	January 24, 2023
Nicox Provides Fourth Quarter 2022 Financial Highlights	January 18, 2023
Nicox Announces Proposed Move to Euronext Growth Paris	January 9, 2022
Half-year liquidity contract statement with Kepler Cheuvreux (as of December 31, 2022)	January 6, 2023

---

2022

Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma	November 7, 2022
Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470	October 31, 2022
Nicox Provides Third Quarter 2022 Financial and Business Highlights	October 19, 2022
Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial	September 19, 2022
Nicox Provides First Half 2022 Business Update and Financial Results	September 16, 2022
Nicox to Participate in Financial and Scientific Events in Q3 2022	August 3, 2022
Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors	July 29, 2022
Nicox Provides Second Quarter 2022 Financial and Business Highlights	July 20, 2022
Nicox: 2022 Extraordinary Shareholder Meeting	July 8, 2022
Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology	July 7, 2022
Nicox Extraordinary General Meeting of July 11, 2022	June 22, 2022
Nicox: 2022 Ordinary Shareholder Meeting	June 14, 2022
Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022	June 3, 2022
Nicox Announces a New Governance Structure	May 16, 2022
Nicox: 2022 Ordinary Shareholder Meeting	May 4, 2022
Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251 and new non-clinical evidence of improved hemodynamic and retinal cell physiology on NCX 470	May 2 2022
Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones	April 28, 2022
Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma	April 11, 2022
Nicox’s Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease	March 2, 2022
Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China	March 1, 2022
Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries	February 23, 2022
Nicox Granted New Patent for NCX 4251 in Japan	February 22, 2022
Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039	February 21, 2022
Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye	February 8, 2022
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2022	January 27, 2022
Nicox Provides Fourth Quarter 2021 Business and Financial Highlights	January 21, 2022
Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030	January 5, 2022

---

2021

Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma	December 16, 2021
Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development	December 13, 2021
Nicox restructure l’accord de financement obligataire avec Kreos Capital et lève 15 millions d’euros avec un placement privé	December 9, 2021
Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease	November 30, 2021
Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe	November 17, 2021
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meeting	November 10, 2021
Nicox Provides Third Quarter 2021 Business and Financial Highlights	October 19, 2021
Nicox to present at the OIS Glaucoma Virtual Innovation Showcase	October 13, 2021
Nicox Launches New Corporate & Investor Website	October 4, 2021
Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model	September 29, 2021
Nicox First Half 2021 Financial Results and Business Update	September 27, 2021
Nicox Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial	September 24, 2021
Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update	16 July 2021
Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board	13 July 2021
Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement	05 July 2021
Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial	02 July 2021
Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial	01 July 2021
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates	25 June 2021
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021	24 June 2021
Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial	01 June 2021
Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico	5 May 2021
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar	4 May 2021
Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod	30 April 2021
Broadcast live and record in audio format of the Ordinary general meeting and Extraordinary General Meeting of April 28, 2021 (in French)	28 April 2021
U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma	27 April 2021
Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment	23 April 2021
U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension	22 April 2021
Nicox Provides First Quarter 2021 Business Update and Financial Highlights	19 April 2021
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL	16 April 2021
Nicox: 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021	13 April 2021
Nicox Ordinary and Extraordinary General Meetings of April 14, 2021	26 March 2021
Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone	23 March 2021
Nicox: 2021 Extraordinary and Ordinary Shareholder Meetings	5 March 2021
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial	4 March 2021
Nicox Announces 2020 Financial Results and 2021 Key Milestones	March 1, 2021
Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds	23 February 2021
Nicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma	15 February 2021
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SOUTH KOREA	9 February 2021
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021	29 January 2021
Nicox Analyst Coverage Initiated by Edison Investment Research	22 January 2021
Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights	20 January 2021
Nicox’s Licensee Bausch + Lomb Launches VYZULTA in Mexico	6 January 2021
Nicox Highlights Successful 2020 Development Progress and Clinical Milestones for 2021	5 January 2021

---

2020

Nicox’s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China	30 December 2020
Nicox’s Licensee Bausch + Lomb Secures Approval of VYZULTA® in Colombia	22 December 2020
Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis	15 December 2020
Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment	11 December 2020
Nicox Analyst Coverage Initiated by Kepler Cheuvreux	25 November 2020
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® in Argentina	23 November 2020
Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma	10 November 2020
Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039	29 October 2020
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial	26 October 2020
Nicox Selects Development Candidate in a New Class of NO-mediated Intraocular Pressure (IOP) Lowering Agents	23 October 2020
Nicox Announces Third Quarter 2020 Business Update and Financial Highlights	20 October 2020
BAUSCH HEALTH ANNOUNCES VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SEVEN COUNTRIES	24 September 2020
Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial	September 23, 2020
Nicox’s ZERVIATE Receives IND Approval in China	22 September 2020
Nicox Announces Senior Management Change	18 September 2020
Nicox First Half 2020 Financial Results and Business Update	10 September 2020
Nicox Partners ZERVIATE™ in the Gulf and Arab Markets	12 August 2020
Nicox: Implementation of a liquidity contract with Kepler Cheuvreux	05 August 2020
Nicox Negotiating €2 million Non-Dilutive Loans Guaranteed by the French State	05 August 2020
Nicox Receives €5 Million Upon Closing of VISUfarma Divestment	31 July 2020
Nicox Second Quarter 2020 Business Update and Financial Highlights	17 July 2020
Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucoma	15 July 2020
Nicox Strengthens Cash Position With Divestment of its VISUfarma Shareholding	10 July 2020
Nicox Partner Ocumension Completes Successful Hong Kong IPO at an approximately US$1,090 Million Valuation	10 July 2020
Nicox to Host Key Opinion Leader Call on NCX 470 for the Treatment of Glaucoma	18 June 2020
Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma	02 June 2020
Nicox First Quarter 2020 Business Update and Financial Highlights	17 April 2020
Nicox Outlines Plans to Progress NCX 4251 into Phase 2b Trial Following Positive Meeting with FDA	08 April 2020
Nicox’s Partner Fera Pharmaceuticals Files Application for Orphan Drug Designation for Naproxcinod in Sickle-Cell Disease	02 April 2020
Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States	31 March 2020
Nicox Updates on ZERVIATE Progress in China and Expands the Countries of its Agreement with Ocumension Therapeutics	11 March 2020
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement	11 March 2020
Nicox’s Partner Secures Additional Approval of VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan	09 March 2020
Nicox Announces 2019 Financial Results and 2020 Key Milestones	06 March 2020
Nicox’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma	05 March 2020
Nicox Receives Formulation Patent Extending NCX 470 U.S. Patent Coverage to 2039	03 February 2020
Nicox Fourth Quarter 2019 Business Update and Financial Highlights	21 January 2020
Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina	16 January 2020
Nicox’s Partner Secures Approval of VYZULTA in Mexico	13 January 2020

---

2019

Nicox’s NCX 4251 Meets Primary Endpoint in Phase 2 Blepharitis Trial and Shows Promising Efficacy in Dry Eye Disease	19 December 2019
Nicox Draws Down Last Tranche from Bond Financing Agreement with Kreos Capital to Support Key Development Programs	17 December 2019
Nicox signs agreement for ZERVIATE in South Korea	06 December 2019
Nicox Raises €12.5 Million to Advance NCX 470 into Phase 3 in Glaucoma	18 November 2019
Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucoma	22 October 2019
Nicox: Third Quarter 2019 Business Update and Financial Highlights	16 October 2019
Nicox Amends Bond Financing Agreement with Kreos and Draws Down Additional €4 Million	10 October 2019
Top Line Results from Glaucoma Dolomites Phase 2 Trial Show Nicox’s NCX 470 Meets Primary Endpoint and Demonstrates Statistical Superiority vs Latanoprost	02 October 2019
Nicox Completes Enrolment of NCX 4251 Phase 2 Trial with Top-Line Results on Track for Q4 2019	27 September 2019
Nicox: First Half 2019 Financial Results and Business Update	17 September 2019
Nicox: Second Quarter 2019 Business Update and Financial Highlights	17 July 2019
Nicox Announces Completion of Enrollment in NCX 470 Phase 2 Clinical Study with Top-Line Results on Track for Early 4Q 2019	16 July 2019
Nicox Receives $3 Million Milestone Payment from Eyevance for ZERVIATE in the U.S.	09 July 2019
Nicox signs agreement for NCX 4251 in China with Ocumension Therapeutics for up to €12 million in milestones plus royalties	02 July 2019
Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019	06 May 2019
Nicox Presents First Data on Promising New Class of Nitric Oxide (NO)-Donating Compounds for Glaucoma at the ARVO 2019 Annual Meeting	03 May 2019
Nicox First Quarter 2019 Business Update and Financial Highlights	18 April 2019
Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis	19 March 2019
Nicox Poster Presentation at AGS 2019 Annual Meeting Discloses Preclinical Data for NCX 4251, a Novel Blepharitis Therapy	18 March 2019
Nicox signs agreement for ZERVIATE in China for up to €17 million in milestone payments plus royalties	15 March 2019
Nicox Announces Presentations at Upcoming Scientific Conferences	12 March 2019
Nicox Announces 2018 Financial Results and 2019 Milestones	06 March 2019
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis	29 January 2019
Nicox Establishes High-Profile Glaucoma Clinical Advisory Board	28 January 2019
Nicox extends cash runway beyond 2020 with bond financing from Kreos Capital of up to €20 million	25 January 2019
Nicox Fourth Quarter 2018 Business Update and Financial Highlights	17 January 2019

---

2018

Nicox Focuses Research Activities on Novel NO-Donating PDE5 Inhibitors for Glaucoma and Enters into Collaboration with Novaliq on Innovative Topical Ophthalmic Formulations	21 December 2018
Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market	17 December 2018
Nicox Postpones NASDAQ Listing Due to Market Volatility	30 October 2018
Nicox Third Quarter 2018 Business Update and Financial Highlights	17 October 2018
Nicox and Fera Pharmaceuticals to Focus on a Rare Disease Indication for Naproxcinod	27 September 2018
Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States	06 September 2018
Nicox First Half 2018 Financial Results and Business Update	06 September 2018
Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertension	02 August 2018
Nicox Second Quarter 2018 Business Update and Financial Highlights	17 July 2018
icox Highlights Recent Progress with Key Programs and Activities	29 June 2018
Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals	06 June 2018
Nicox Provides First Quarter 2018 Business and Financial Results	04 May 2018
Nicox announces the presentation of scientific data for NCX 667 at ARVO 2018	03 May 2018
Nicox: Opening of U.S. Development Office in Research Triangle Park, North Carolina	25 April 2018
Nicox Announces Improved Financial Terms from Bausch + Lomb for VYZULTA	14 March 2018
Nicox provides 2018 Outlook and 2017 Estimated Financial Results	06 March 2018
Nicox Appoints Tomas Navratil, Ph.D., as Head of Development	03 January 2018

---

2017

Nicox Recaps 2017 Achievements, Provides Update on Commercial Availability of VYZULTA and Outlines 2018 Activities	19 December 2017
Nicox Highlights VYZULTA approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives	03 November 2017
BAUSCH + LOMB AND NICOX ANNOUNCE FDA APPROVAL OF VYZULTA™ (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%	02 November 2017
Nicox Provides Third Quarter 2017 Business Update and Cash Position	24 October 2017
Nicox and pSivida Enter Strategic Collaboration Agreement to Develop Sustained Release Drug to Lower Intraocular Pressure in Patients with Glaucoma	10 October 2017
Nicox announces licensing agreement with Eyevance for commercialization of ZERVIATE in the United States	21 September 2017
Nicox first half 2017 business and financial update	08 September 2017
Nicox announces that its Exclusive Licensee Submits response to CRL for latanoprostene bunod ophthalmic solution, 0.024%	18 August 2017
Nicox announces €26.25 million financing	15 August 2017
Press Release concerning latanoprostene bunod ophthalmic solution, 0.024%	08 August 2017
Nicox announces the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to former Aciex shareholders following the US FDA’s approval of the new drug application in the US for ZERVIATE (cetirizine ophthalmic solution) 0.24%.	08 June 2017
Nicox receives FDA approval of ZERVIATE (cetirizine ophthalmic solution) 0.24%	31 May 2017
Mrs. Lauren P. Silvernail appointed to Nicox Board of Directors	17 May 2017
Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017	09 May 2017
Nicox first quarter 2017 business update and cash position	27 April 2017
Nicox announces PDUFA date for ZERVIATE NDA	11 April 2017
Nicox: Business Update and 2016 Financial Results	31 March 2017
Bausch + Lomb and Nicox announce PDUFA date for novel glaucoma candidate latanoprostene bunod	20 March 2017
Nicox resubmits AC-170 (ZERVIATE1) NDA to the U.S. FDA	09 March 2017
Bausch + Lomb and Nicox resubmit US New Drug Application for novel glaucoma candidate latanoprostene bunod	27 February 2017
Nicox announces the presentation of NCX 667 scientific data at AOPT 2017	21 February 2017
Nicox provides clinical and regulatory update for NCX 4251 in blepharitis	05 January 2017